Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.
Katharina F KörholzMiriam A FüllerMarc HenniesMalcolm HolterhusSusanne HagedornMartina AhlmannHeike ThorerBirgit BurkhardtAndreas H GrollPublished in: Paediatric drugs (2022)
Letermovir was effective in controlling CMV infection in seropositive paediatric allogeneic HCT recipients and was overall well tolerated. Pending completion of the still ongoing paediatric investigation plans, letermovir will be an important adjunct to our options for control of infectious complications in this special population.
Keyphrases
- stem cell transplantation
- intensive care unit
- end stage renal disease
- emergency department
- bone marrow
- chronic kidney disease
- newly diagnosed
- single cell
- peritoneal dialysis
- risk factors
- high dose
- health insurance
- low dose
- signaling pathway
- patient reported outcomes
- smoking cessation
- kidney transplantation
- replacement therapy